On June 18, 2026, a new publication addressing performance-enhancing peptides that modulate the GH-IGF1 axis was released in the journal Frontiers in Endocrinology. The publication, titled "The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration," references hexarelin among the compounds discussed.
Hexarelin remains classified as an unapproved research compound. This publication is noted here as a new entry in the scientific literature discussing hexarelin within the broader context of GH-IGF1 axis modulating peptides.
No specific findings, data, or conclusions from this publication have been detailed here. Readers interested in the full scope of the discussion should consult the publication directly through the journal or PubMed listing.
For general background on hexarelin, readers can consult the compound overview.